May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Deniz Can Guven: Toripalimab phase I data in refractory CCA
Jan 28, 2025, 06:20

Deniz Can Guven: Toripalimab phase I data in refractory CCA

Deniz Can Guven, The Editorial Board Member of BMC Cancer and Medical Oncologist at Health Sciences University, shared a recent article by Amit Mahipal et al. on X: 

“Toripalimab phase I data in refractory CCA:

  • The first study with Toripalimab in the US.
  • Manageable side effects.
  • Acceptable disease control (40%).
  • Could additional IO options improve access?

Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study

Authors: Amit Mahipal, Milind Javle, Judy Wang, Todd M. Bauer, David L. Bajor, Anthony D. Elias, Anthony Shields, Elizabeth Davis, Sant Chawla, Howard Safran, John D. Powderly, Gina D’Amato, Christian F. Meyer, Xiongwen Tang, Sheng Yao and Patricia Keegan

Deniz Can Guven

More posts featuring Deniz Can Guven.